SCHEMBL6765841

SCHEMBL6765841

Cc1ccc(Sc2ccccc2C=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.48
MAPT P10636 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
POLB P06746 1/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 2/20 0.45
TSHR P16473 1/20 0.45
TDP1 Q9NUW8 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HKDC1 Q2TB90 1/20 0.44
CYP2C9 P11712 3/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
HTR1A P08908 2/20 0.43
CYP2D6 P10635 2/20 0.43
HTR3A P46098 2/20 0.43
LMNA P02545 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL193869 0.84 KMT2A (0.50) L3MBTL1MAPTSMN1; SMN2HTTALDH1A1
SCHEMBL7188592 0.83 ALDH1A1 (0.45) MAPTSMN1; SMN2HTTALDH1A1TSHR
SCHEMBL1466237 0.81 MEN1 (0.43) L3MBTL1SMN1; SMN2HTTALDH1A1TSHR
SCHEMBL7195380 0.81 NR1H2 (0.46) MAPTALDH1A1TSHRTDP1MEN1
SCHEMBL2271692 0.81 HDAC1 (0.57) L3MBTL1MAPTNPSR1SMN1; SMN2HTT
SCHEMBL6762455 0.81 HPGD (0.51) L3MBTL1MAPTNPSR1SMN1; SMN2HTT
SCHEMBL5320711 0.81 ALDH1A1 (0.54) POLBALDH1A1MEN1KMT2ACYP2C9
SCHEMBL8687784 0.81 HTR1A (0.46) MAPTALDH1A1TSHRTDP1MEN1
SCHEMBL11121836 0.80 CYP1A2 (0.53) L3MBTL1MAPTNPSR1SMN1; SMN2ALDH1A1
SCHEMBL30548756 0.80 CYP1A2 (0.53) L3MBTL1MAPTNPSR1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119192125-A Preparation method of oxygen/thioxanthene compound 湖南科技大学 2024-12-27 CN disclosed
CN-119192126-A Preparation method of oxygen/thioxanthone compound 湖南科技大学 2024-12-27 CN disclosed
CN-104710345-B For preparing 4(2‑(4 aminomethyl phenyl sulfenyls))Compound, its preparation method and the application of Phenylpiperidine 江苏恩华药业股份有限公司 2017-09-05 CN disclosed
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-09-30 US disclosed
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase ABBOTT LABORATORIES 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040121994-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 L3MBTL1 2206/4885MAPT 4703/4885NPSR1 1830/4885
US-20040192680-A1 Novel amides that activate soluble guanylate cyclase GUCY1A1, GUCY1B1, GUCY1A2 L3MBTL1 2206/4885MAPT 4703/4885NPSR1 1830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.